Prometic to present at the American Chemical Society

    MONTREAL, April 4 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX:PLI)
("ProMetic") announced today that Dr. Robert Rohwer, Pathogen Removal and
Diagnostics Technology Inc.'s ("PRDT") academic co-founder and Dr. Patrick
Gurgel, ProMetic's Senior Research Scientist will present at the American
Chemical Society's ("ACS") 235th National Meeting in New Orleans from April 6
- 10, 2008. Drs Rohwer and Gurgel will be speaking during the symposium
honoring Dr. Ruben Carbonell's nomination as Fellow of the Industrial and
Engineering Chemistry ("I&EC") Division of the ACS.
    Dr. Carbonell is an academic co-founder of PRDT, a ProMetic joint venture
with the American Red Cross, along with Dr. Robert Rohwer.
    Dr. Rohwer will be speaking on April 7, 2008 at 16:25 (EDT) and the title
of his presentation is "Managing the risks from blood-associated TSE
infectivity with prion affinity ligands".
    Dr. Gurgel's lecture titled "Development of a device for prion reduction
based on affinity ligand" will be presented on April 8, 2008 at 13:30 (EDT)
    The accompanying presentations will be available on ProMetic's website at
http://www.prometic.com/en/scientific_information_et.htm following the
respective lecture.

    About PRDT Academic co-founders

    Dr. Ruben Carbonell, is the Frank Hawkins Kenan Distinguished Professor
of Chemical and Biomolecular Engineering, and Director of the Golden LEAF
Biomanufacturing Training and Education Center ("BTEC") at North Carolina
State University. Dr. Carbonell's recent research in bioseparations led to the
identification of a specific ligand for the prion protein responsible for the
transmission of mad cow disease in humans. This ligand is being used to remove
prion protein from blood products. Dr. Carbonell is the recipient of a number
of teaching and research awards, including NC State's Alumni Distinguished
Graduate Professorship and the Alexander Quarles Holladay Medal. Dr. Carbonell
joined the faculty at NC State as a full professor in 1984. He served as head
of the Department of Chemical Engineering from 1994 to 1999. Dr. Carbonell
also directs the William R. Kenan, Jr. Institute for Engineering, Technology
and Science and is a fellow of the American Institute of Chemical Engineers
and the Industrial and Engineering Chemistry Division of the American Chemical
Society.

    Dr. Robert G. Rohwer is the Director of the Molecular Neurovirology
Laboratory, Veteran's Affairs Medical Center and Associate Professor of
Neurology, at the University of Maryland School of Medicine. For 30 years
Dr. Rohwer has conducted research on transmissible spongiform encephalopathies
("TSEs"), a class of fatal neurodegenerative diseases that include
Creutzfeldt-Jakob disease, which infects humans, scrapie, which infects sheep
and goats, and Bovine Spongiform Encephalopathy ("BSE"), a newly emergent
disease that affects both cattle and humans. Dr. Rohwer's studies on the
kinetics of inactivation of the TSE agents have provided the scientific
foundation for disinfection guidelines in the U.S. and worldwide. More
recently Dr. Rohwer and his laboratory team have conducted critical
experiments establishing the level, distribution and transmissibility of TSE
infectivity in blood, the results of which have been used to shape government
policies on TSE risk management around the world. Dr. Rohwer consults on the
management of TSE risks for the World Health Organization, the European
Commission, Health Canada, the U.S. Food and Drug Administration, the American
Red Cross, the U.S. Department of Agriculture and numerous commercial clients
in the biotechnology, pharmaceutical, agribusiness and related industries,
including ProMetic Life Sciences Inc.

    About Pathogen Removal and Diagnostic Technologies Inc.

    Pathogen Removal and Diagnostic Technologies Inc. ("PRDT") is a joint
venture established in April 2002 by The American Red Cross and ProMetic Life
Sciences Inc., and allows for the exchange of technology and knowledge between
the two organizations. PRDT's main goal is to develop products and devices to
remove and detect different pathogens from biological sources. This research
augments work that ProMetic, the American Red Cross and PRDT's scientific
founders have been conducting independently for many years.

    About ProMetic Life Sciences Inc.

    ProMetic Life Sciences Inc. (www.prometic.com) is a biopharmaceutical
company specialized in the research, development, manufacture and marketing of
a variety of commercial applications derived from its proprietary Mimetic
Ligand(TM) technology. This technology is used in large-scale purification of
biologics and the elimination of pathogens. ProMetic is also active in
therapeutic drug development with the mission to bring to market effective,
innovative, lower cost, less toxic products for the treatment of hematology
and cancer. Its drug discovery platform is focused on replacing complex,
expensive proteins with synthetic "drug-like" protein mimetics. Headquartered
in Montréal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and
Canada, manufacturing facilities in the U.K. and business development
activities in the U.S., Europe, Asia and in the Middle-East.

    Forward Looking Statements

    This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and uncertainties.
These statements are "forward-looking" because they are based on our current
expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks
affect our business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited to,
ProMetic's ability to develop, manufacture, and successfully commercialize
value-added pharmaceutical products, the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of ProMetic to take advantage of business opportunities
in the pharmaceutical industry, uncertainties related to the regulatory
process and general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or results to
materially differ from our current expectations on page 21 of ProMetic's
Annual Information Form for the year ended December 31, 2007, under the
heading "Risk Factors". As a result, we cannot guarantee that any
forward-looking statement will materialize. We assume no obligation to update
any forward-looking statement even if new information becomes available, as a
result of future events or for any other reason, unless required by applicable
securities laws and regulations.

For further information: Company Inquiries: Pierre Laurin, President and
CEO, ProMetic Life Sciences Inc., (514) 341-2115, p.laurin@prometic.com;
Dominic Sicotte, Echoes Financial Network Inc., (514) 842-9551,
dsicotte@echoesfinancial.com; Anne Leduc, Manager, Investor Relations &
Communications, ProMetic Life Sciences Inc., (514) 341-2115,
a.leduc@prometic.com; Investor Relations: Bruce Voss, Lippert/Heilshorn &
Associates, (310) 691-7100, BVoss@lhai.com; Kim Golodetz, Lippert/Heilshorn &
Associates, KGolodetz@lhai.com, (212) 838-3777; Media Relations: Jules
Abraham, Lippert/Heilshorn & Associates, (212) 838-3777, JAbraham@lhai.com